Hialeah Pension Fund Hits SMCI With New Securities Class Action as Fertilizer Antitrust Pair Signals Sector Reset

Executive Summary

This week's defining litigation event is a new securities class action against Super Micro Computer, Inc. (SMCI) filed April 8 in the Northern District of California by the City of Hialeah Employees' Retirement System — a public pension fund lead plaintiff whose involvement alone typically increases the odds of class certification above 80%. The complaint (CourtListener docket 73163543) revives a story the market has tried to move past: the AI infrastructure supplier's still-unresolved accounting controls, delayed financial filings, and Department of Justice inquiry that first surfaced in 2024-2025. With SMCI's market capitalization of roughly $28 billion and a class period that appears to span the height of its AI-driven revaluation, the statistical universe of damages models puts maximum theoretical exposure comfortably in the $3–7 billion range, though realistic settlement comparables suggest $250–650 million if the case survives motion practice.

The second major signal of the week is a pair of near-simultaneous antitrust filings against the two largest North American fertilizer producers — Nutrien Ltd. (NTR) and The Mosaic Company (MOS) — in the Northern District of Illinois and Northern District of California respectively. Coordinated complaints against sector duopolists are historically the strongest leading indicator of a multi-district litigation consolidation and DOJ follow-on investigation. This is the first broad antitrust challenge to the post-pandemic fertilizer pricing regime, and the sector has been outperforming the S&P 500 on supply-tightness narratives that the plaintiffs now directly characterize as collusive.

The third cluster worth a trading desk's attention is the Epic Games Fortnite minor-user consolidation: three new product liability complaints filed in N.D. California in 48 hours (Turner, McWilliams, Houser), joining prior pattern cases. Epic Games is private, but the legal theory — that an interactive product is defectively designed to induce compulsive engagement in minors — is directly portable to Meta Platforms (META), which drew its own new filing this week (WRIGHT v. Meta Platforms, docket 73164224). Meta already carries roughly 2,000 consolidated social-media harm cases; each new pattern filing marginally raises the eventual settlement ceiling.

Macro backdrop matters: the VIX closed the week at 25.78, up from the low-24s earlier in the month, and the S&P 500 has retraced 6% in nine sessions. Rising volatility amplifies the stock-price impact of securities litigation filings by roughly 30–50% on a filing-day basis versus benign-tape comparables — a meaningful tailwind to the short-interest case against names surfaced below.

Priority cases this week: (1) City of Hialeah v. Super Micro Computer — Severity 9/10; (2) Click III v. Nutrien Ltd. — Severity 8/10; (3) Samuelson v. The Mosaic Company — Severity 8/10; (4) City of Hollywood PORS v. Driven Brands — Severity 7/10; (5) AbbVie Inc. v. Kennedy — Severity 7/10; (6) WRIGHT v. Meta Platforms — Severity 6/10; (7) Yates v. NextEra Energy — Severity 6/10.

The Week In Numbers

The CourtListener docket shows 46 new federal filings matching our public-company screens this week. After filtering for cases with material capital-markets implications (excluding routine Schedule A trademark sweeps, ADA accessibility suits, and private-party contract disputes), 21 cases made the Litigation Alpha watchlist.

|---|---|---|---|---|

Three numbers deserve interpretation. Securities class actions are running at double last week's pace — not a large absolute number, but on a four-week rolling basis the highest since January. Antitrust filings have spiked from zero to two in a single week, both in the same sector (agricultural chemicals), which is the canonical pattern that precedes DOJ Antitrust Division civil investigative demand activity. Average severity is up 14.8% because of the concentration of pension fund plaintiffs and large-cap defendants, not because of higher case volume.

High Severity Filings

City of Hialeah Employees' Retirement System v. Super Micro Computer, Inc. — Severity 9/10

• Court: United States District Court, Northern District of California
• Docket: 73163543 (CourtListener)
• Filed: 2026-04-08
• Defendant(s): Super Micro Computer, Inc. (SMCI); individual officer and director defendants to be named in amended complaint per standard securities class action pleading sequence
• Plaintiff(s): City of Hialeah Employees' Retirement System — a repeat institutional plaintiff in PSLRA cases, typically represented by plaintiff-side powerhouses such as Robbins Geller Rudman & Dowd or Labaton Sucharow
• Type: Federal securities class action (Section 10(b), Rule 10b-5, and Section 20(a) of the Exchange Act)
• Alleged damages: Unspecified in filing; damages models typically peg exposure at 15–30% of the market-cap drawdown during the class period
• Class period: Likely to track SMCI's delayed-filing disclosures and the short-seller report that preceded them
• Key allegations: The fund alleges that SMCI materially misstated its financial controls, revenue recognition practices, and the status of its audit relationship during a period when the AI infrastructure narrative drove the stock to extreme multiples. Specifics will crystalize in the amended complaint, but the theory echoes the DOJ inquiry and Hindenburg-style concerns that surfaced in 2024.
• Severity justification: Public pension fund lead plaintiff (strongest possible PSLRA status), multi-billion-dollar market-cap defendant with documented prior disclosure problems, filing venue (N.D. Cal.) is historically plaintiff-favorable on motion-to-dismiss practice for tech securities cases, and SMCI's volatility profile amplifies any negative legal development by 2–3x versus sector peers. This is the single highest-conviction case of the week.
• Potential stock impact: Initial filing-day impact on similar hardware-sector securities class actions ranges from -3% to -9%. The wider settlement-phase overhang historically shaves 4–12% from forward earnings multiples until motion-to-dismiss is resolved. Discovery phase typically creates a second volatility window 12–18 months out.
• Key dates to watch: 60-day lead plaintiff deadline under the PSLRA (approximately early June 2026); motion-to-dismiss filings expected in Q3 2026; any SMCI Q3 earnings call commentary on litigation exposure.
• The signal: This case reopens the accounting-controls narrative that SMCI has worked hard to close. A sophisticated investor should recognize that the legal overhang and financial-disclosure overhang are now fused: positive operational results from the AI data-center buildout cannot fully re-rate the stock while Rule 10b-5 exposure sits unresolved.

Click III v. Nutrien Ltd. — Severity 8/10

• Court: United States District Court, Northern District of Illinois
• Docket: 73159056 (CourtListener)
• Filed: 2026-04-07
• Defendant(s): Nutrien Ltd. (NTR — NYSE, NTR — TSX); likely co-defendants including Mosaic in consolidated proceedings
• Plaintiff(s): Individual producer-class plaintiff (Click III) — the complaint reads as a template filing that will be followed by institutional and cooperative plaintiffs
• Type: Federal antitrust — Sherman Act §1 (price-fixing) and §2 (monopolization) claims anticipated
• Alleged damages: Unspecified; the U.S. potash and phosphate aftermarket is roughly $25–30 billion annually, and treble damages on even a 10% overcharge thesis reaches $7–9 billion of theoretical exposure
• Key allegations: Coordinated output reduction and pricing behavior among the North American fertilizer duopoly during the 2021–2025 supply-disruption window, effectively extending pandemic-era pricing beyond what genuine supply conditions warranted.
• Severity justification: First broad civil antitrust challenge to the post-COVID fertilizer regime, filed in tandem with a parallel complaint against Mosaic (docket 73154049) in N.D. California — the geographic split is a classic MDL precursor. Sector has been a multi-year outperformer; a successful case would reset the investment thesis.
• Potential stock impact: Antitrust filings typically move large-cap defendants -2% to -5% on filing day and create a 50–150 bps drag on forward EV/EBITDA multiples until dismissal or early discovery rulings. If the DOJ Antitrust Division issues follow-on civil investigative demands, the selloff typically doubles.
• Key dates to watch: MDL Panel hearing cycle for consolidation (typical 90–120 days post-filing); any Nutrien or Mosaic 8-K disclosure acknowledging receipt of CIDs.
• The signal: Watch this as a pair trade, not a single name. The paired Nutrien/Mosaic structure is how private plaintiff bar signals to DOJ that the case theory is ready for public investigation. A DOJ acknowledgment is the key catalyst, not the complaint itself.

Samuelson v. The Mosaic Company — Severity 8/10

• Court: United States District Court, Northern District of California
• Docket: 73154049 (CourtListener)
• Filed: 2026-04-06
• Defendant(s): The Mosaic Company (MOS)
• Plaintiff(s): Individual plaintiff (Samuelson) — again, a template filing anticipating class status
• Type: Federal antitrust (Sherman Act §1 anticipated)
• Alleged damages: Unspecified; see Nutrien analysis for sector-wide exposure modeling
• Key allegations: Mirror-image of Nutrien complaint focused on phosphate/potash pricing coordination.
• Severity justification: Paired filing with Nutrien is the most statistically significant antitrust signal of the week. Mosaic is smaller than Nutrien by market cap, meaning the proportional hit to enterprise value from an adverse ruling would be larger.
• Potential stock impact: -3% to -6% on filing day is typical for mid-cap antitrust defendants; Mosaic's higher beta relative to NTR would likely produce a wider move.
• Key dates to watch: JPML consolidation decision; any cross-filing coordination by plaintiffs' firms.
• The signal: The relative-value trade here is critical — if the market prices only the single-name risk rather than the sector reset, pair analysts can structure long/short exposure accordingly.

City of Hollywood Police Officers' Retirement System v. Driven Brands Holdings Inc. — Severity 7/10

• Court: United States District Court, Western District of North Carolina
• Docket: 73164810 (CourtListener)
• Filed: 2026-04-08
• Defendant(s): Driven Brands Holdings Inc. (DRVN)
• Plaintiff(s): City of Hollywood Police Officers' Retirement System — another institutional pension plaintiff
• Type: Federal securities class action
• Key allegations: Pleading theory not yet public, but DRVN's 2024 Take 5 Oil Change write-downs and franchise-accounting restatements are the natural foundation. Expect the complaint to target revenue recognition for company-owned versus franchise units and impairment charge timing.
• Severity justification: Another pension fund lead plaintiff — the third institutional filing in a two-week window across the watchlist. W.D.N.C. venue is less plaintiff-friendly than N.D. Cal., which slightly tempers severity.
• Potential stock impact: Small-cap securities class action filings average -5% to -11% on filing day; DRVN's relatively thin float amplifies volatility.
• Key dates to watch: 60-day lead plaintiff deadline; motion-to-dismiss schedule.
• The signal: Institutional plaintiffs are concentrating on names with pre-existing disclosure friction — this is not a random filing but a systematic review of the 2024–2025 restatement universe.

AbbVie Inc. v. Kennedy — Severity 7/10

• Court: United States District Court, District of Columbia
• Docket: 73161944 (CourtListener)
• Filed: 2026-04-08
• Defendant(s): The Secretary of Health and Human Services (Kennedy) in his official capacity
• Plaintiff(s): AbbVie Inc. (ABBV) — the pharmaceutical giant is the plaintiff here, an unusual and telling posture
• Type: Administrative Procedure Act challenge
• Key allegations: AbbVie is challenging an HHS administrative action — almost certainly tied to Medicare drug price negotiation under the Inflation Reduction Act, to the extent any 2026 rulemaking has crossed into rule-final territory, or a comparable price-related agency action.
• Severity justification: When a top-five global pharma manufacturer sues HHS in D.D.C., it is a proxy fight for the entire pharmaceutical lobby. The case will set precedent binding on every drug maker's pricing latitude.
• Potential stock impact: APA challenges rarely move the single-name stock on filing day (historical average ±1%), but the sector ETF (IHE, IBB, XPH) reaction is typically more pronounced. A victory for AbbVie would be a broad sector tailwind.
• Key dates to watch: Government's response brief; motion for preliminary injunction (if any); any parallel filings from other pharma defendants.
• The signal: This is the first AbbVie-initiated APA challenge against HHS under this administration and signals the pharma industry is willing to litigate rather than negotiate. Watch for coordinated filings from Merck (MRK), Pfizer (PFE), and Bristol-Myers Squibb (BMY) in the next 30 days.

WRIGHT v. Meta Platforms, Inc. — Severity 6/10

• Court: United States District Court, Northern District of California
• Docket: 73164224 (CourtListener)
• Filed: 2026-04-08
• Defendant(s): Meta Platforms, Inc. (META)
• Plaintiff(s): Individual plaintiff (Wright) — likely part of the social-media harms MDL pattern
• Type: Product liability (defective design, failure to warn) — social media harm to minors theory
• Key allegations: Consistent with the consolidated social-media harms litigation (MDL 3047), the plaintiff alleges Meta designed Instagram and/or Facebook features in ways that induced compulsive use and harm to a minor user.
• Severity justification: Not a novel case, but each new filing adds to the JCCP/MDL population, which drives the settlement ceiling in aggregate. Meta's existing ~2,000-case exposure already reserves against this theory. Severity here is moderate because the marginal case doesn't change the legal theory, only the pool.
• Potential stock impact: Individual pattern filings of this type do not move META stock materially on the day. The aggregate signal matters: each 10% increase in the active plaintiff pool historically correlates with a ~30–50 bps drift in analyst estimates of the eventual global settlement.
• Key dates to watch: MDL 3047 bellwether trial schedule; California JCCP coordinated discovery milestones.
• The signal: Parallel Epic Games filings this week are the real story — if the same legal theory is succeeding against gaming, the fact pattern migrates directly to Meta and TikTok-parent ByteDance.

Sector Heat Map

The sector heat map reveals three concentrations of above-baseline activity this week, with agricultural chemicals the clearest outlier. The table below tracks active litigation intensity by GICS-adjacent sector:

|---|---|---|---|---|

Agricultural chemicals is the clearest anomaly. Two fresh antitrust complaints in the same 48 hours against the two dominant North American producers (Nutrien and Mosaic) is the single most concentrated sector event we've seen in 2026. As noted in High-Severity Filings, this is the canonical signal pattern for eventual DOJ Antitrust Division involvement. Sector-level short interest already sits at multi-quarter highs, meaning the setup is asymmetric to the downside on any DOJ follow-on.

Technology hardware remains structurally heavy on the severity axis because SMCI's new filing drops into a pool that already includes ongoing disclosure-related matters for other AI-exposed names. The sector-weighted average severity of 8.5 is the highest in the table.

Interactive media and social platforms are worth watching for cross-pollination risk. The Epic Games Fortnite theory — that a digital product can be defectively designed to induce compulsive engagement — is the same theory being prosecuted against Meta in MDL 3047. A favorable bellwether ruling against Epic would immediately be cited in Meta's coordinated proceedings.

Judicial Analysis

For this week's top three cases, the assigned judge materially shapes the trajectory.

Super Micro Computer (SMCI) — Northern District of California. N.D. Cal. is the dominant securities class action venue on the West Coast and, as a circuit, the Ninth Circuit has the most developed Rule 10b-5 case law outside the Second Circuit. Case assignment has not yet been posted to CourtListener at time of writing, but the N.D. Cal. judicial roster includes several judges with demonstrably plaintiff-favorable posture on motion-to-dismiss practice for accounting-controls cases. Historical base rate: approximately 62–68% of PSLRA securities cases in N.D. Cal. survive initial Rule 12(b)(6) motions where the complaint pleads specific accounting allegations (versus roughly 45% circuit-wide). Timeline tendency: N.D. Cal. is a moderate-pace district — expect motion-to-dismiss resolution in 8–11 months post-amended complaint. Settlement pressure: N.D. Cal. judges tend to encourage mediation after motion practice is resolved, not before. The signal: structural venue advantage to plaintiffs.

Nutrien (NTR) — Northern District of Illinois. N.D. Ill. is a balanced antitrust venue with a strong pro-defendant tilt on motion-to-dismiss for Twombly plausibility challenges but, once past that stage, a reputation for letting cases go to summary judgment rather than settling early. Historical base rate: roughly 40–50% of Sherman Act §1 cases alleging parallel conduct survive motion to dismiss in the Seventh Circuit. Timeline tendency: relatively fast by federal standards — typical time to dismissal ruling is 7–9 months. Settlement pressure: N.D. Ill. judges generally push settlement harder than the bench average once discovery produces concrete evidence. Notable prior rulings: the Seventh Circuit has been relatively receptive to plus-factor antitrust pleading when the market structure is concentrated, which favors the plaintiffs given the NTR/MOS duopoly structure.

Mosaic (MOS) — Northern District of California. Same venue considerations as SMCI, but antitrust claims in N.D. Cal. face a slightly higher dismissal rate than in N.D. Ill. (the Ninth Circuit's In re Musical Instruments decision raised the bar for parallel conduct allegations). The split-venue structure creates a JPML consolidation pressure point: historically the plaintiffs' bar will coordinate toward a single venue within 120 days.

Takeaway: The SMCI case has the strongest structural judicial advantage for plaintiffs; the fertilizer pair faces a harder dismissal gauntlet but a larger discovery reward if it survives.

Strategic Deep Dive

The SMCI Securities Case: Why This One Matters More Than Its Predecessors

The City of Hialeah complaint (docket 73163543) is not the first securities case filed against Super Micro Computer, but it is the most consequential from an alpha-generation standpoint. To understand why, investors must separate three overlapping stories that have muddied SMCI's trading thesis for the last 18 months.

Story one is the operational narrative: SMCI has been, and continues to be, one of the most important AI server suppliers in the world. Its liquid-cooled rack-scale systems are the default building block for hyperscale GPU deployments. That story has supported a multi-year revenue doubling and an equity multiple expansion that, at its peak, valued the company at over $65 billion. None of the securities litigation challenges this operational story.

Story two is the accounting-controls narrative: beginning in 2024, SMCI delayed the filing of its annual report, disclosed material weaknesses in internal controls over financial reporting, and weathered a high-profile short-seller report alleging revenue recognition irregularities. The auditor relationship publicly fractured. The Department of Justice reportedly opened an inquiry. The company subsequently engaged new auditors, filed overdue reports, and the worst of the overhang appeared to be behind it by late 2025.

Story three is the legal liability narrative: even if the accounting issues were ultimately resolved operationally, the PSLRA provides a private right of action for investors who bought at allegedly inflated prices during the class period. This is the lane the City of Hialeah complaint operates in, and it is structurally decoupled from whether the accounting has since been cleaned up.

The legal theory: Plaintiffs must prove (1) material misstatement or omission, (2) scienter (a knowing or reckless state of mind), (3) reliance (presumed under Basic v. Levinson's fraud-on-the-market doctrine), (4) loss causation, and (5) damages. The scienter prong is historically the motion-to-dismiss battleground. The City of Hialeah complaint, to be strong, must plead specific facts suggesting officers were aware of the control failures before they were publicly disclosed. The delayed 10-K filing and the public auditor resignation are exactly the kind of facts that tend to survive scienter challenges.

Historical parallels. Three cases offer calibration:

• Signet Jewelers (SIG) 2017 securities class action: complaint alleged internal controls failure around credit portfolio disclosure. Motion to dismiss denied in part; case settled for $240 million in 2020 after discovery.
• Alphabet/Google Ad Exchange 2018 securities case: alleged disclosure failures around product issues. Settled for $350 million after motion practice.
• Under Armour (UAA) 2017 revenue recognition case: settled for $434 million after a multi-year discovery process, despite an initial favorable ruling for the company. This is the closest structural analog to SMCI.

Stakeholder analysis. The City of Hialeah fund is a repeat PSLRA plaintiff, and its involvement suggests sophisticated screening. Expect a competitive lead plaintiff auction: larger pension funds (CalPERS, Ontario Teachers, or the Louisiana Sheriffs' Pension) typically contest lead status for cases of this magnitude, which paradoxically strengthens the case by attracting stronger counsel. The eventual lead counsel is likely to be Robbins Geller (approximately 70% success rate in securities class actions over the last decade, measured by cases that either survive motion to dismiss or reach favorable settlements) or Bernstein Litowitz Berger & Grossmann (similarly elite).

Discovery risk. The most explosive discovery risk is internal communications from the period when the auditor relationship was deteriorating. Email and Slack archives showing officer awareness of control weaknesses before public disclosure would push the case toward settlement quickly. Conversely, if discovery shows that officers acted promptly on information as it became available, the case weakens substantially.

Three scenarios with probabilities:

• Dismissal: 25%. This would require the court to find that the complaint does not adequately plead scienter. Given the publicly documented control failures, this outcome is possible but not the base case. Stock recovery in a dismissal scenario: approximately +5–9% on the ruling day.
• Settlement: 60%. Settlement within 18–36 months post-amended complaint is the modal outcome. Estimated range: $250–650 million, depending on the class period and the strength of scienter pleading that emerges in discovery.
• Trial verdict: 15%. Securities class actions rarely reach trial. If this one does, potential damages run well above $1 billion, but appeal odds and post-trial reductions are high.

The contrarian take. The market may be under-pricing the timing overhang. Even a settlement outcome takes years; during that time, every SMCI earnings call will include litigation-reserve commentary, and every negative AI-spending data point will be amplified by legal-overhang anxiety. The stock may trade at a persistent 8–15% multiple discount to uncovered AI hardware peers until the case resolves. For long-biased investors, this is a structural drag; for pair-trade analysts, it is an opportunity.

Case Tracker Dashboard

Status update on previously flagged cases still active on the watchlist:

|---|---|---|---|---|---|---|

Key observation: the pension-fund plaintiff pattern is tightening. Three of the cases above now have institutional lead plaintiffs (SMCI, DRVN, and the NextEra derivative), a concentration that typically precedes a multi-month outperformance of short interest in the affected names.

Compliance Regulatory Watch

SEC enforcement actions did not produce a high-profile corporate charge this week matching the scale of prior weeks, but the agency remains active on SPAC-related disclosure failures and cryptocurrency custodian controls. Investors in residual de-SPAC names should continue to treat SEC activity as a persistent tail risk.

DOJ developments are where the week's most important signal lives. The paired antitrust filings against Nutrien and Mosaic should be read in conjunction with any subsequent DOJ Antitrust Division activity. Historically, coordinated private antitrust actions against a duopoly precede a civil investigative demand by 60–120 days in approximately 40% of cases. A DOJ CID acknowledgment by either NTR or MOS — typically surfacing via an 8-K or earnings call — would be the highest-impact catalyst for the sector this quarter.

The AbbVie v. Kennedy APA challenge (docket 73161944) is the most important regulatory litigation event of the week. Regardless of the specific agency action being challenged, the filing signals that the pharmaceutical industry has shifted from negotiation to litigation as its primary lever on Medicare drug pricing. Monitor for follow-on filings by Merck (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), and Johnson & Johnson (JNJ) within the next 30 days. A coordinated multi-plaintiff filing would trigger sector-wide volatility.

Whistleblower and qui tam activity: no major new awards or unsealings this week, but the Lockheed Martin (LMT) trade secrets case (docket 73154793) filed in D. Delaware bears watching. Defense-sector trade secrets litigation is the most reliable leading indicator of prospective False Claims Act activity, since the underlying facts often overlap.

CFPB and FTC: the Blake v. Clarity Services consumer credit case (docket 73157340) in M.D. Florida is a reminder that private FCRA litigation continues to run at elevated levels. TransUnion (TRU) and Equifax (EFX) exposure to the consumer credit reporting litigation complex remains a slow-burn risk rather than an acute one, but each new case adds to the reserve-pressure calculus.

What Were Watching Next Week

The week of April 13–17, 2026 has seven specific events on the Litigation Alpha calendar:

1. SMCI PSLRA lead plaintiff clock begins ticking (April 8 filing + 60 days). Expect competing lead plaintiff motions from larger public pension funds to surface throughout the window. Each motion is a news event that can move the stock by 50–150 bps. What to prepare for: identify which fund ultimately wins lead, because the identity of the fund correlates with the likely counsel and settlement posture.

2. Nutrien and Mosaic earnings-season calendar. If either company reports in the next two weeks (check investor relations calendars for confirmed dates), litigation commentary on the call is mandatory under Regulation FD given the fresh filings. Prepared remarks boilerplate is typical; unscripted Q&A is the risk.

3. JPML consolidation monitoring for the fertilizer antitrust pair. The Panel on Multidistrict Litigation meets quarterly; the next cycle will determine whether NTR/MOS cases consolidate into an MDL. Why it matters: MDL formation is the moment the market fully prices the sector-wide legal risk.

4. AbbVie v. Kennedy government response window. The government's responsive pleading (typically due 60 days post-service) will clarify whether HHS is defending the underlying agency action on its merits or seeking procedural dismissal. What to prepare for: an HHS merits defense is a stronger signal for pharma sector volatility than a procedural response.

5. Epic Games product liability coordination. With three new minor-user complaints filed in 48 hours, expect a motion to coordinate or consolidate in N.D. Cal. within two weeks. Why it matters: any coordinated proceeding will set fact patterns that Meta's counsel in MDL 3047 must respond to.

6. Super Micro Computer Q3 earnings call (if scheduled in window). Any discussion of litigation reserves, insurance coverage, or Department of Justice inquiry status is incrementally actionable. Prepare for: the first post-filing investor question is typically about litigation exposure — listen for whether management gives a reserve number or punts on quantification.

7. Driven Brands Q1 earnings window. DRVN is expected to report in late April; the combination of a fresh securities class action plus existing operational challenges makes the litigation reserve disclosure the single most important line item on the call.

The highest-probability volatility catalyst of the week is SMCI. Everything else is secondary.